Three EU Countries Strike Landmark Joint Zolgensma Pricing Deal
BeNeLuxA, the cross-country medicines access initiative, says it is now the “gold standard” for voluntary collaboration in Europe after a ground-breaking deal was reached with Novartis.
You may also be interested in...
Joint price negotiations for Orchard’s gene therapy Libmeldy could follow outcome of multi-country health technology assessment.
Joint procurement is of growing interest in the EU as a means of providing access to expensive innovative medicines.
Cross-country drug access coalition BeNeLuxA is reviewing the costly one-off gene therapy for children with metachromatic leukodystrophy.